Could Making a New Woolly Mammoth Help Human Health?
Jan 3, 2025
auto_awesome
Ben Lamm, co-founder and CEO of Colossal Biosciences, is on a mission to resurrect the woolly mammoth through cutting-edge genetic engineering. He discusses how these efforts could restore biodiversity and ecosystems. Lamm shares insights on leveraging this technology for human health, including cancer resistance found in elephants. The conversation also touches on the ethical implications of de-extinction and the complexities of rewilding these ancient species, making a compelling case for the intersection of conservation and biotechnology.
Colossal Biosciences aims to tackle biodiversity loss through the de-extinction of species like the woolly mammoth using advanced genetic technologies.
The company’s research not only focuses on conservation but also seeks to leverage genetic insights from elephants for potential advancements in cancer treatments.
Deep dives
The Vision of De-Extinction
Colossal Biosciences is focused on genetically engineering hybrid species that resemble extinct animals such as the woolly mammoth, Tasmanian tiger, and dodo. This initiative is part of a broader movement aimed at addressing the imminent loss of biodiversity, with projections indicating that up to 50% of species may vanish by 2050. The company aims to utilize innovative techniques across various scientific fields, including genome engineering and synthetic biology, to create de-extinction tools. By starting with less controversial animals like the woolly mammoth, the company believes they can explore the ecological benefits of rewilding without facing significant public opposition.
Technological Innovations for Conservation
Colossal is employing cutting-edge technologies such as CRISPR and artificial wombs to facilitate the revival of extinct species and improve conservation efforts. A significant project in the company's portfolio is the genetic rescue of the northern white rhino, which utilizes similar techniques to enhance genetic diversity in the remaining embryos. The approach involves gathering ancient DNA from frozen specimens to assemble genomes and then using advanced bioengineering to create viable embryos through surrogate species, like Asian elephants for mammoths. These developments showcase the potential for synthetic biology to not only resurrect lost species but also apply those innovations to other areas of conservation.
Linking Extinction and Human Health
Colossal's work extends beyond conservation into the realm of human health, particularly by exploring how genetic research on elephants can contribute to cancer treatments. The company has spun off a computational biology platform focused on drug discovery, leveraging the unique genetic traits of elephants, which exhibit lower cancer rates than expected due to a protein known as P53. By regulating this protein in their research, Colossal aims to uncover new insights that could lead to advancements in cancer care. While the primary focus remains on conservation, the overarching goal is to ensure that the technologies developed can benefit human health, emphasizing a dual-purpose approach to their scientific endeavors.
Colossal Biosciences wants to create new animals that resemble extinct creatures like the woolly mammoth, thanks to advancements in genetic engineering and synthetic biology. In this conversation from the WSJ’s Future of Everything Festival in May 2024, Colossal Biosciences co-founder and CEO Ben Lamm discusses how the de-extinction of species could help address the loss of biodiversity and benefit ecosystems. He tells Future of Everything editorial director Stefanie Ilgenfritz about his plans for monetizing the technology, and how it could be used for human health.